| Symbol | NRSNW |
|---|---|
| Name | NEUROSENSE THERAPEUTICS LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, 4672562, Israel |
| Telephone | +972 9 - 7996183 |
| Fax | — |
| — | |
| Website | https://www.neurosense-tx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001875091 |
| Description | NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimers disease and Parkinsons disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Additional info from NASDAQ: |
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
Read moreNeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
Read moreNew Form F-3/A - NeuroSense Therapeutics Ltd. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001213900-26-083328 <b>Size:</b> 1 MB
Read moreNeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
Read moreNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
Read moreNeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
Read moreNeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
Read moreNeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06185543 | A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-control… | Phase2 | Alzheimer Disease | Terminated | 2023-11-19 | 2025-09-30 | ClinicalTrials.gov |
| NCT05436678 | A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC … | Phase1 | Pharmacokinetics | Completed | 2022-07-26 | 2022-10-20 | ClinicalTrials.gov |
| NCT05357950 | A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Stud… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2022-05-31 | 2024-11-04 | ClinicalTrials.gov |
| NCT05232461 | A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult … | Phase1 | Pharmacokinetics | Completed | 2022-04-08 | 2022-08-30 | ClinicalTrials.gov |
| NCT04090684 | Ciprofloxacin/Celecoxib Combination in Patients With ALS | Phase1 | ALS (Amyotrophic Lateral Sclerosis) | Completed | 2019-12-09 | 2022-01-20 | ClinicalTrials.gov |
| NCT04165850 | Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients Wi… | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2019-11-25 | 2021-01-19 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Fixed dose combination Ciprofloxacin/Celecoxib | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04165850 |
| Fixed dose combination Ciprofloxacin/Celecoxib | Other | Phase PHASE1 | ALS (Amyotrophic Lateral Sclerosis) | COMPLETED | NCT04090684 |
| Celecoxib 200mg | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05232461 |
| Ciprofloxacin 750 MG | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05232461 |
| PrimeC-ER 748 mg | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05232461 |
| Celecoxib 200mg | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05436678 |
| Ciprofloxacin 750 MG | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05436678 |
| PrimeC 748 mg | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05436678 |
| Placebo | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05357950 |
| PrimeC | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT05357950 |
| Placebo | Other | Phase PHASE2 | Alzheimer Disease | TERMINATED | NCT06185543 |
| PrimeC | Other | Phase PHASE2 | Alzheimer Disease | TERMINATED | NCT06185543 |
| PrimeC 748 mg | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05436678 |
| Placebo | DRUG | Phase PHASE2 | Alzheimer Disease | RECRUITING | NCT06185543 |
| PrimeC | DRUG | Phase PHASE2 | Alzheimer Disease | RECRUITING | NCT06185543 |
| Celecoxib 200mg | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05436678 |
| Ciprofloxacin 750 MG | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05436678 |
| PrimeC-ER 748 mg | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05232461 |
| Fixed dose combination Ciprofloxacin/Celecoxib | DRUG | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04165850 |